Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.8
-16.2 (-0.51%)

 

  • STI Straits Times Index
    3,166.8
    -16.2 (-0.51%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,599.5
    -4.8 (-0.30%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,754.1
    -36.1 (-0.13%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,985.7
    7.5 (0.25%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    21,960.7
    -40.6 (-0.18%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,276.6
    39.9 (0.64%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,070.7
    8.4 (0.41%)
    Index delayed 20 minutes
  • XAO XAO
    6,791.2
    -10.5 (-0.15%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 726.6M
  • Value: 896.1M
  • Rise: 134
  • Fall: 155
  • Unch: 544

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.088-0.005
TEE Intl0.046+0.004
YZJ Shipbldg SGD1.050-0.030
Spackman0.013+0.001
Mapletree Ind Tr2.400+0.070
Keppel DC Reit1.970+0.040
Kep Infra Tr0.525+0.005
LionGold0.001-
Medtecs Intl0.039+0.007
Mapletree Com Tr2.220+0.060

World Indices

World Indices
Name Last Change
Nasdaq 8,186.0 +32.5
HSI 26,754.1 -36.1
HSCEI 10,478.5 -23.9
Jakarta 6,276.6 +39.9
Nikkei 225 21,960.7 -40.6
SSE Comp 2,985.7 +7.5
Shanghai A 3,127.8 +7.9
Shanghai B 271.6 +0.9
PSE Comp 0.0
KOSPI 2,070.7 +8.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

EXTRAWELL PHAR EXTRAWELL PHAR
Quotes 15 Minutes Delayed. Updated at 18 Sep 2019 15:59
Last (HKD): 0.096 Change: +0.010 High: 0.096 Remarks: -
Change (%): +11.63 Low: 0.087
Open 0.087 Yesterday's Close 0.086
Buy Price 0.088 Sell Price 0.096
Buy Volume ('000) 100 Sell Volume ('000) 20
Cumulative Volume ('000) 190 Cumulative Value 16,720
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a 0.02679 Trailing EPS (HKD) e 0.02679 NAV (HKD) b 0.2319
PE a 3.583 Trailing PE f 3.583 Price / NAV b 0.4140
Dividend (HKD) d - Cash In Hand (HKD) g 0.0711 Issued & Paid-up Shares c 2,390,000,000
Dividend Yield (%) d - Price / Cash In Hand g 1.350 Treasury Shares h -
Beta - 75 Daysi 0.144 R-Squared - 75 Days(%)i 0.06 Market Cap (M) 229.440
Beta - 500 Daysi 0.332 R-Squared - 500 Days (%)i 0.97 Enterprise Value (M) 614.688
Piotroski F Score 7 Exchange Code 858 Par Value ( HKD ) 0.01000
52 Weeks Volatility (%) 48.42 6-Month VWAP 0.103 Free Float (%) 39.6
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 29 Jul 2015.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference EXTRAWELL PHAR HKEx 229.440 3.583 3.583 0.4140 -
Industry Biotechnology HKEx 49,843.539 13.262 14.053 5.5937 2.735
Local Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Local Peer SINO BIOPHARM HKEx 135,076.224 12.606 13.010 3.9683 0.681
Local Peer WUXI BIO HKEx 97,099.387 130.002 101.632 9.9953 -
Local Peer BEIGENE HKEx 62,029.143 - - 5.1096 -
Local Peer GENSCRIPT BIO HKEx 31,656.040 190.370 - 8.9272 -
Local Peer 3SBIO HKEx 31,734.100 20.978 25.533 3.1278 -
Local Peer FRONTAGE HKEx 8,693.081 98.678 98.671 4.4992 -
Local Peer VIVA BIOTECH HKEx 7,496.719 69.898 69.898 3.8920 -
Local Peer HAOHAI BIOTEC HKEx 5,857.658 11.930 13.222 1.3791 1.598
Local Peer ASCLETIS-B HKEx 4,225.001 - - 1.0964 -
Local Peer CKLIFE SCIENCES HKEx 3,459.985 13.158 13.140 0.8287 2.778
Local Peer ESSEX BIO-TECH HKEx 2,870.883 12.423 10.968 2.7302 -
Other Local Peers LEE'S PHARM (HKEx), UNI-BIO GROUP (HKEx), BBI LIFE SCI (HKEx), CT ENTERPRISE (HKEx), REGENT PACIFIC (HKEx), BIOSINO BIO-TEC (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 117,973.181 14.054 14.824 10.9295 2.818
Global Peer GILEAD SCIENCES INC NASDAQ 83,800.996 15.362 14.072 3.7054 3.488
Global Peer CSL ASX 106,410.911 39.662 39.662 14.2200 1.132
Global Peer CELGENE CORP NASDAQ 69,881.863 17.272 13.258 6.9527 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 45,238.160 21.579 20.424 8.9228 -
Global Peer BIOGEN INC NASDAQ 44,027.499 9.937 8.316 3.3990 -
Global Peer ILLUMINA INC NASDAQ 43,845.690 53.082 46.744 10.1213 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 31,662.760 12.953 15.302 3.2455 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 24,178.397 311.575 18.130 2.3789 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 23,643.355 74.821 22.055 4.9807 0.802
Other Global Peers INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), SEATTLE GENETICS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), EXELIXIS INC (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), Lonza (SGX), REPLIGEN CORP (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), CRISPR THERAPEUTICS AG (NASDAQ), GENOMIC HEALTH INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), UNIQURE N.V. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), REGENXBIO INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ALECTOR INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), OPKO HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), INTREXON CORP (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), POLYNOVO LIMITED (ASX), DICERNA PHARMACEUTICALS INC. (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), OMEROS CORP (NASDAQ), NEXTCURE INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ARVINAS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), VANDA PHARMACE INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), AVITA MEDICAL LTD (ASX), VOYAGER THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), AVROBIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ACHILLION PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), PERSONALIS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), MAGENTA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), XBIOTECH INC (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), NEXT SCIENCE LTD (ASX), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), RESTORBIO INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PROTHENA CORP PLC (NASDAQ), KADMON HLDGS INC (NYSE), AVID BIOSERVICES INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), ARDELYX INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GERON CORP (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), COMPUGEN (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), TELIX PHARMACEUTIC (ASX), ELOXX PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), CHIASMA INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), ATHERSYS INC (NASDAQ), PFENEX INC (NYSE American), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), DPHARMA (Bursa), CALITHERA BIOSCIENCES INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), KAMADA (NASDAQ), GLYCOMIMETICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), XOMA CORP (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), AVEO PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NOVAVAX INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), IMV INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), AXCELLA HEALTH INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), APTOSE BIOSCIENCES INC (NASDAQ), NANTKWEST INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), T2 BIOSYSTEMS INC (NASDAQ), SESEN BIO INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VERASTEM INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), RESAPP HEALTH LIMITED (ASX), FENNEC PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), VACCINEX INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), CEL-SCI CORP (NYSE American), PHYLOGICA LIMITED (ASX), ALPINE IMMUNE SCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), INFLARX N V (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), PORT (SET), NEWLINK GENETICS CORP (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ORGENESIS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), CHAMPIONS ONCOLOGY INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), EQUILLIUM INC (NASDAQ), ARAVIVE INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), INMUNE BIO INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), IBIO INC (NYSE American), SURFACE ONCOLOGY INC (NASDAQ), IMUGENE LIMITED (ASX), VERMILLION INC (NASDAQ), IMMUTEP LTD (ASX), CIDARA THERAPEUTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), IVERIC BIO INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIOCARDIA INC (NASDAQ), EVOGENE LTD (NASDAQ), ORTHOCELL LIMITED (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), CELLDEX THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ONCOSIL MEDICAL LIMITED (ASX), ORAGENICS INC (NYSE American), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), BIOTRON (ASX), AZURRX BIOPHARMA INC (NASDAQ), ZAFGEN INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SENESTECH INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), RHINOMED LIMITED (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), TOCAGEN INC (NASDAQ), HISTOGENICS CORP (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), BIOCEPT INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), MEMPHASYS LTD (ASX), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ISORAY INC (NYSE American), PATRYS LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ADALTA LTD (ASX), PRECIPIO INC (NASDAQ), ATYR PHARMA INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), BIONOMICS LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), Suntar Eco-City^ (SGX), IMMURON LIMITED (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLMID LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NANOVIRICIDES INC (NYSE American), CONATUS PHARMACEUTICALS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), TROVAGENE INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), BIOXYNE LIMITED (ASX), REXAHN PHARMACEUTICALS INC (NASDAQ), MEDIBIO LIMITED (ASX), XENETIC BIOSCIENCES INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), CYCLACEL PHARMA IN (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ADVAXIS INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), MGRC (Bursa), AVECHO BIOTECHNOLOGY LTD (ASX), MEGASUN (Bursa), PLUS THERAPEUTICS INC (NASDAQ), OPGEN INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), NOVITA HEALTHCARE LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SPHERIX INC (NASDAQ), QT Vascular (SGX), AIM IMMUNOTECH INC (NYSE American), TBG DIAGNOSTICS LTD (ASX), CCP TECHNOLOGIES LTD (ASX), BPH ENERGY LIMITED (ASX), NANOLLOSE LTD (ASX), NEURALSTEM INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), ALCHEMIA LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.015
+18.52 %
10 Days -+0.021
+28.00 %
20 Days -+0.014
+17.07 %
Medium Term Return 3 Months -+0.006
+6.67 %
6 Months --0.012
-11.11 %
1 Year --0.023
-19.33 %
Long Term Return 2 Years --0.099
-50.77 %
3 Years --0.169
-63.77 %
5 Years --0.284
-74.74 %
Annualised Return Annualised --
-24.06 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.069 - 0.134 Change From 1 Year Low +0.027 % Change From 1 Year Low (%) +39.13
Change From 1 Year High -0.038 % Change From 1 Year High (%) -28.36
2 Years Range 0.069 - 0.265 Change From 2 Years Low +0.027 % Change From 2 Years Low (%) +39.13
Change From 2 Years High -0.169 % Change From 2 Years High (%) -63.77
5 Years Range 0.069 - 0.730 Change From 5 Years Low +0.027 % Change From 5 Years Low (%) +39.13
Change From 5 Years High -0.634 % Change From 5 Years High (%) -86.85
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Extrawell Pharmaceutical Holdings Ltd. engages in the marketing and distribution of pharmaceutical products. It operates through the following segments: Manufacturing, Trading, and Gene Development. The Manufacturing segment includes the development, manufacture, and sale of pharmaceutical products. The Trading segment covers the marketing and distribution of imported pharmaceutical products. The Gene Development segment focuses on the commercial exploitation and development of genome-related technology. The company was founded on December 8, 1998 and is headquartered in Hong Kong.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Sep 2019 0.086 0.086 0.086 0.086 540,000 0.0860
16 Sep 2019 0.078 0.100 0.078 0.090 2,510,000 0.0896
13 Sep 2019 0.074 0.078 0.074 0.078 130,000 0.0745
12 Sep 2019 0.075 0.078 0.075 0.078 40,000 0.0763
11 Sep 2019 0.080 0.081 0.079 0.079 370,000 0.0798
10 Sep 2019 0.080 0.083 0.080 0.081 870,000 0.0818
09 Sep 2019 0.079 0.079 0.079 0.079 10,000 0.0790
06 Sep 2019 0.080 0.084 0.078 0.079 2,710,000 0.0809
05 Sep 2019 0.074 0.079 0.074 0.076 250,000 0.0776
04 Sep 2019 0.072 0.078 0.072 0.077 770,000 0.0755
03 Sep 2019 0.072 0.076 0.072 0.075 270,000 0.0754
02 Sep 2019 0.078 0.078 0.071 0.077 410,000 0.0726
30 Aug 2019 0.074 0.078 0.074 0.078 880,000 0.0743
29 Aug 2019 0.076 0.076 0.076 0.076 - -
28 Aug 2019 0.072 0.076 0.072 0.076 1,260,000 0.0740
27 Aug 2019 0.077 0.081 0.070 0.070 5,310,000 0.0759
26 Aug 2019 0.077 0.078 0.077 0.078 60,000 0.0775
23 Aug 2019 0.079 0.083 0.079 0.079 2,500,000 0.0799
22 Aug 2019 0.081 0.081 0.080 0.081 350,000 0.0802
21 Aug 2019 0.081 0.081 0.081 0.081 790,000 0.0810
20 Aug 2019 0.073 0.083 0.071 0.082 760,000 0.0810
19 Aug 2019 0.080 0.080 0.080 0.080 - -
Summary
Current 2 Weeks
(04 Sep 2019 to 17 Sep 2019)
0.072 0.100 0.072 0.086 8,200,000 -
Previous 2 Weeks
(21 Aug 2019 to 03 Sep 2019)
0.081 0.100 0.072 0.075 11,830,000 -
4 Weeks from
(24 Jul 2019 to 20 Aug 2019)
0.095 0.100 0.072 0.082 11,630,000 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.